TOPLINE In patients with immunoglobulin (Ig)G4-related disease, treatment with rilzabrutinib — an oral, reversible Bruton tyrosine kinase inhibitor (BTKi) — resulted in around 70% of patients remaining flare-free and off glucocorticoids (GCs) or immunosuppressants for up to 52 weeks. Reductions in disease activity were observed in those with prior rituximab exposure and those who were …
Read More
Rilzabrutinib May Be Promising in IgG4-Related Disease
